STAT3 Expression, Molecular Features, Inflammation Patterns, and Prognosis in a Database of 724 Colorectal Cancers

Purpose: STAT3 is a transcription factor that is constitutively activated in some cancers. It seems to play crucial roles in cell proliferation and survival, angiogenesis, tumor-promoting inflammation, and suppression of antitumor host immune response in the tumor microenvironment. Although the STAT3 signaling pathway is a potential drug target, clinical, pathologic, molecular, or prognostic features of STAT3-activated colorectal cancer remain uncertain. Experimental Design: Utilizing a database of 724 colon and rectal cancer cases, we evaluated phosphorylated STAT3 (p-STAT3) expression by immunohistochemistry. The Cox proportional hazards model was used to compute mortality HR, adjusting for clinical, pathologic, and molecular features, including microsatellite instability (MSI), the CpG island methylator phenotype (CIMP), LINE-1 methylation, 18q LOH, TP53 (p53), CTNNB1 (β-catenin), JC virus T-antigen, and KRAS, BRAF, and PIK3CA mutations. Results: Among the 724 tumors, 131 (18%) showed high-level p-STAT3 expression (p-STAT3-high), 244 (34%) showed low-level expression (p-STAT3-low), and the remaining 349 (48%) were negative for p-STAT3. p-STAT3 overexpression was associated with significantly higher colorectal cancer–specific mortality [log-rank P = 0.0020; univariate HR (p-STAT3-high vs. p-STAT3-negative): 1.85, 95% CI: 1.30–2.63, Ptrend = 0.0005; multivariate HR: 1.61, 95% CI: 1.11–2.34, Ptrend = 0.015]. p-STAT3 expression was positively associated with peritumoral lymphocytic reaction (multivariate OR: 3.23; 95% CI: 1.89–5.53, P < 0.0001). p-STAT3 expression was not associated with MSI, CIMP, or LINE-1 hypomethylation. Conclusions: STAT3 activation in colorectal cancer is associated with adverse clinical outcome, supporting its potential roles as a prognostic biomarker and a chemoprevention and/or therapeutic target. Clin Cancer Res; 17(6); 1452–62. ©2011 AACR.

[1]  Shuji Ogino,et al.  CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer , 2008, Gut.

[2]  F. J. Ramos,et al.  Pharmacogenomic and pharmacoproteomic studies of cetuximab in metastatic colorectal cancer: biomarker analysis of a phase I dose-escalation study. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  S. Ishikawa,et al.  Activation of DNA methyltransferase 1 by EBV latent membrane protein 2A leads to promoter hypermethylation of PTEN gene in gastric carcinoma. , 2009, Cancer research.

[4]  E. Bruyneel,et al.  Implication of STAT3 signaling in human colonic cancer cells during intestinal trefoil factor 3 (TFF3) -- and vascular endothelial growth factor-mediated cellular invasion and tumor growth. , 2005, Cancer research.

[5]  Timothy C Wang,et al.  Inflammation and cancer: IL-6 and STAT3 complete the link. , 2009, Cancer cell.

[6]  G. Ball,et al.  NKG2D Ligand Expression in Human Colorectal Cancer Reveals Associations with Prognosis and Evidence for Immunoediting , 2009, Clinical Cancer Research.

[7]  J. Bosset,et al.  Prognostic value of phosphorylated STAT3 in advanced rectal cancer: a study from 104 French patients included in the EORTC 22921 trial , 2010, Journal of Clinical Pathology.

[8]  H. Baumann,et al.  Targeting signal transducer and activator of transcription signaling pathway in leukemias. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  F. Greten,et al.  IKK/NF‐κB and STAT3 pathways: central signalling hubs in inflammation‐mediated tumour promotion and metastasis , 2009, EMBO reports.

[10]  Toshiyuki Nakayama,et al.  Activation of STAT3 is a marker of poor prognosis in human colorectal cancer. , 2006, Oncology reports.

[11]  D. Sargent,et al.  Obesity Is an Independent Prognostic Variable in Colon Cancer Survivors , 2010, Clinical Cancer Research.

[12]  P. Laird,et al.  CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer , 2006, Nature Genetics.

[13]  R. Moriggl,et al.  Signal Transducer and Activator of Transcription 3 Activation Promotes Invasive Growth of Colon Carcinomas through Matrix Metal loproteinase Induction , 2007 .

[14]  Shuji Ogino,et al.  Precision of pyrosequencing assay to measure LINE-1 methylation in colon cancer, normal colonic mucosa, and peripheral blood cells. , 2010, The Journal of molecular diagnostics : JMD.

[15]  L. Coussens,et al.  Inflammation and cancer , 2002, Nature.

[16]  Shengdian Wang,et al.  Accumulation of Foxp3+ T Regulatory Cells in Draining Lymph Nodes Correlates with Disease Progression and Immune Suppression in Colorectal Cancer Patients , 2010, Clinical Cancer Research.

[17]  Li Lin,et al.  A novel small molecule, LLL12, inhibits STAT3 phosphorylation and activities and exhibits potent growth-suppressive activity in human cancer cells. , 2010, Neoplasia.

[18]  H. Seno,et al.  Signal transducers and activators of transcription 3 activation is involved in nuclear accumulation of beta-catenin in colorectal cancer. , 2006, Cancer research.

[19]  Pui-Kai Li,et al.  Novel STAT3 phosphorylation inhibitors exhibit potent growth-suppressive activity in pancreatic and breast cancer cells. , 2010, Cancer research.

[20]  G. Lau,et al.  STAT3 implicated in the development of colon cancer: a step closer for targeted therapy? , 2010, Gastroenterology.

[21]  K. Mimori,et al.  Jumonji Domain Containing 1A Is a Novel Prognostic Marker for Colorectal Cancer: In vivo Identification from Hypoxic Tumor Cells , 2010, Clinical Cancer Research.

[22]  B. Aggarwal,et al.  Targeting Inflammatory Pathways for Prevention and Therapy of Cancer: Short-Term Friend, Long-Term Foe , 2009, Clinical Cancer Research.

[23]  D. Chauhan,et al.  Nifuroxazide inhibits survival of multiple myeloma cells by directly inhibiting STAT3. , 2008, Blood.

[24]  S. Ogino,et al.  PIK3CA mutation in colorectal cancer: relationship with genetic and epigenetic alterations. , 2008, Neoplasia.

[25]  Shuji Ogino,et al.  JC virus T-antigen in colorectal cancer is associated with p53 expression and chromosomal instability, independent of CpG island methylator phenotype. , 2009, Neoplasia.

[26]  J. Ahn,et al.  Clinical impact of phosphorylated signal transducer and activator of transcription 3, epidermal growth factor receptor, p53, and vascular endothelial growth factor receptor 1 expression in resected adenocarcinoma of lung by using tissue microarray , 2010, Cancer.

[27]  H. Aburatani,et al.  Three DNA Methylation Epigenotypes in Human Colorectal Cancer , 2009, Clinical Cancer Research.

[28]  L. Klampfer.  The role of signal transducers and activators of transcription in colon cancer. , 2008, Frontiers in bioscience : a journal and virtual library.

[29]  J. Meyerhardt,et al.  Correlation of beta-catenin localization with cyclooxygenase-2 expression and CpG island methylator phenotype (CIMP) in colorectal cancer. , 2007, Neoplasia.

[30]  Hua Yu,et al.  STATs in cancer inflammation and immunity: a leading role for STAT3 , 2009, Nature Reviews Cancer.

[31]  G. Milano,et al.  Identification of a functional EGF-R/p60c-src/STAT3 pathway in colorectal carcinoma: analysis of its long-term prognostic value. , 2008, Cancer biomarkers : section A of Disease markers.

[32]  Mari Mino-Kenudson,et al.  Lymphocytic Reaction to Colorectal Cancer Is Associated with Longer Survival, Independent of Lymph Node Count, Microsatellite Instability, and CpG Island Methylator Phenotype , 2009, Clinical Cancer Research.

[33]  R. Moriggl,et al.  Signal transducer and activator of transcription 3 activation promotes invasive growth of colon carcinomas through matrix metalloproteinase induction. , 2007, Neoplasia.

[34]  M. Karin,et al.  IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer. , 2009, Cancer cell.

[35]  Ying-Xuan Chen,et al.  Inhibition of JAK1, 2/STAT3 signaling induces apoptosis, cell cycle arrest, and reduces tumor cell invasion in colorectal cancer cells. , 2008, Neoplasia.

[36]  Shuji Ogino,et al.  Aspirin and the risk of colorectal cancer in relation to the expression of COX-2. , 2007, The New England journal of medicine.

[37]  G. Dranoff,et al.  Dual roles for immunity in gastrointestinal cancers. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  J. Berlin,et al.  Lack of Correlation between Epidermal Growth Factor Receptor Status and Response to Panitumumab Monotherapy in Metastatic Colorectal Cancer , 2010, Clinical Cancer Research.

[39]  Kurt Zatloukal,et al.  Persistent STAT3 activation in colon cancer is associated with enhanced cell proliferation and tumor growth. , 2005, Neoplasia.

[40]  Ozge Canli,et al.  gp130-mediated Stat3 activation in enterocytes regulates cell survival and cell-cycle progression during colitis-associated tumorigenesis. , 2009, Cancer cell.

[41]  M. Loda,et al.  Sensitive sequencing method for KRAS mutation detection by Pyrosequencing. , 2005, The Journal of molecular diagnostics : JMD.

[42]  D. Levy,et al.  Identification of a Stat3-dependent transcription regulatory network involved in metastatic progression. , 2009, Cancer research.

[43]  D. Germain,et al.  Targeting the Cytoplasmic and Nuclear Functions of Signal Transducers and Activators of Transcription 3 for Cancer Therapy , 2007, Clinical Cancer Research.

[44]  C. Logsdon,et al.  ZIP4 Regulates Pancreatic Cancer Cell Growth by Activating IL-6/STAT3 Pathway through Zinc Finger Transcription Factor CREB , 2010, Clinical Cancer Research.

[45]  R. Palmqvist,et al.  The Role of the CpG Island Methylator Phenotype in Colorectal Cancer Prognosis Depends on Microsatellite Instability Screening Status , 2010, Clinical Cancer Research.

[46]  U. McDermott,et al.  Prognostic Significance of TRAIL Signaling Molecules in Stage II and III Colorectal Cancer , 2010, Clinical Cancer Research.

[47]  J. Meyerhardt,et al.  Prognostic significance and molecular associations of 18q loss of heterozygosity: a cohort study of microsatellite stable colorectal cancers. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[48]  M. Loda,et al.  Evaluation of markers for CpG island methylator phenotype (CIMP) in colorectal cancer by a large population-based sample. , 2007, The Journal of molecular diagnostics : JMD.

[49]  B. Aggarwal,et al.  Signal Transducer and Activator of Transcription‐3, Inflammation, and Cancer , 2009, Annals of the New York Academy of Sciences.

[50]  M. Loda,et al.  Combined analysis of COX-2 and p53 expressions reveals synergistic inverse correlations with microsatellite instability and CpG island methylator phenotype in colorectal cancer. , 2006, Neoplasia.

[51]  L. Terracciano,et al.  Clinicopathological and protein characterization of BRAF‐ and K‐RAS‐mutated colorectal cancer and implications for prognosis , 2010, International journal of cancer.